# Research Foundation for the State University of New York

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/research-foundation-for-the-state-university-of-new-york/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 94 |
| Citations | 1,761 |
| City | Albany |
| Country | United States |
| Description | Research Foundation for the State University of New York is a research organisation in Albany, United States. OpenAlex records 89 works and 1,761 citations for it. 1 researchers list it as their most recent affiliation. |
| Homepage | http://www.rfsuny.org/ |
| OpenAlex ID | https://openalex.org/I4210111819 |
| Region | New York |
| Researchers | 1 |
| ROR ID | https://ror.org/01sfc5174 |
| Type | nonprofit |
| Works | 89 |

## University papers

- [2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis](https://scholariq.org/papers/2012-update-of-the-2008-american-college-of-rheumatology-recommendations-for-the/)
- [IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial](https://scholariq.org/papers/il-6-receptor-inhibition-with-tocilizumab-improves-treatment-outcomes-in/)
- [Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis](https://scholariq.org/papers/placebo-controlled-trial-of-tofacitinib-monotherapy-in-rheumatoid-arthritis/)
- [Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study](https://scholariq.org/papers/tofacitinib-cp-690-550-in-patients-with-rheumatoid-arthritis-receiving/)
- [The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo](https://scholariq.org/papers/the-safety-and-efficacy-of-a-jak-inhibitor-in-patients-with-active-rheumatoid/)
- [Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis](https://scholariq.org/papers/tofacitinib-in-combination-with-nonbiologic-disease-modifying-antirheumatic/)
- [Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu](https://scholariq.org/papers/tocilizumab-inhibits-structural-joint-damage-in-rheumatoid-arthritis-patients/)
- [Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial](https://scholariq.org/papers/ixekizumab-for-the-treatment-of-patients-with-active-psoriatic-arthritis-and-an/)
- [Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis](https://scholariq.org/papers/tumour-necrosis-factor-antagonist-use-and-associated-risk-reduction-of/)
- [A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone](https://scholariq.org/papers/a-phase-iib-dose-ranging-study-of-the-oral-jak-inhibitor-tofacitinib-cp-690-550/)

## University researchers

- [Joel M. Kremer](https://scholariq.org/researchers/joel-m-kremer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.